Results from two separate Phase 1 studies show sobetirome, a selective
thyroid hormone receptor beta agonist, reduced levels of low-density
lipoprotein versus placebo
ANN ARBOR, Mich., Jan. 29 /PRNewswire/ -- QuatRx Pharmaceuticals, a privately-held biopharmaceutical company developing compounds for the treatment of major endocrine, metabolic and cardiovascular diseases, today announced results from two Phase 1 clinical studies with its novel lipid lowering compound, sobetirome (formerly QRX-431), in development for the treatment of elevated LDL cholesterol (also known as "bad cholesterol") levels. The results of the studies indicated LDL lowering with both single and multiple doses of sobetirome in a healthy volunteer population not enriched for elevated LDL levels. Sobetirome was generally well tolerated in both studies. Sobetirome is a new selective thyroid hormone receptor beta agonist that may activate reverse cholesterol transport.
"We are excited and extremely encouraged by these Phase 1 results indicating that sobetirome was generally well tolerated and showed lowering of LDL levels. We look forward to replicating these results in larger Phase 2 and 3 trials. We believe this new compound has potential as monotherapy or in combination with statins for the many patients who are unable to tolerate current therapies or who fail to achieve lipid treatment goals with statins alone," said Robert L. Zerbe, M.D., chief executive officer and president of QuatRx.
Lipid-lowering effects in both single and multiple doses were seen in
the randomized, double-blind, placebo-controlled Phase 1 studies of
sobetirome. In the single dose study of 32 subjects, low-density
lipoprotein (LDL) cholesterol levels decreased by up to 22% in subjects
receiving up to 450 micrograms of sobetirome, compared to 2% in subjects
who received placebo. The greatest reductions were observed 72 hours after
|SOURCE QuatRx Pharmaceuticals|
Copyright©2008 PR Newswire.
All rights reserved